Latin America Melanoma Diagnostics and Therapeutics Market - Segmented by Type of Cancer and Geography 2017 - 2022

  • ID: 4388228
  • Report
  • Region: America, America (exc North), Latin America
  • 120 pages
  • Mordor Intelligence
1 of 3
The Latin America melanoma diagnostics and therapeutics market was valued at USD 106 million in 2015 and is expected to reach USD 234 million by 2020.

Melanoma is one of the serious types of skin cancer that develops from pigment-containing cells called melanocytes. The market for melanoma diagnostics and therapeutics is increasing at a significant rate due to an increase in the prevalence of melanoma and improvement in healthcare facilities. In addition, government initiatives and technical advancements boost the market growth.

The market for melanoma can be segmented based on:

Types

Superficial spreading melanoma

Nodular melanoma

Lentigno maligna melanoma

Acral lentiginous melanoma

Amelanotic melanoma

Others

Cutaneous malignant melanoma

Melanoma of vulva

Vaginal melanoma or melanoma of black passage

Cancer Stage

Stage 0

Stage I

Stage II

Stage III

Stage IV

Diagnosis

Dermatoscopy

Sentinel lymph node biopsy

X-rays

Blood tests

CT scan

Ultrasound

Treatment

Treatment for early stage melanoma

Surgery (Excision and Mohs surgery)

Treatment for advanced stage melanoma

Chemotherapy

Biological therapy

Radiotherapy

Targeted therapy

Immune therapy

Surgery(Lymphadenectomy)

Geographical regions

Abbott Diagnostics, Agilent Technologies, Roche, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Sanofi, Qiagen N.V. Company and Teva Pharmaceuticals to name a few, are the key players of this market.

Drivers

Increase in melanoma incident cases

Approval and uptake of premium-priced products

Effective immunotherapies

Label extension of current therapies into the new settings

Government initiatives

Restraints

Lack of awareness in some developing regions

High cost associated with the therapy

Economic crisis

Regulatory issues

SPECIALITIES OF THIS REPORT

The report will be useful in gaining an exhaustive understanding of the regional market. It will also be of assistance in providing a comprehensive analysis of the major trends, innovations and associated prospects for market growth over the coming half a decade.

The report will be an ideal source material for industry consultants, manufacturers and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.

The report contains wide range of information about the leading market players and the major strategies adopted by them.

WHAT THE REPORT OFFERS

Market definition along with identification of key drivers and restraints for the market.

Market analysis with region specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares.

Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Introduction
1.1 Report Description
1.2 Research Methodology
2. Executive Summary
3. Market Overview
3.1 Market Definition
3.2 Market Drivers
3.2.1 Increasing incidences of Melanoma cases
3.2.2 The approval and uptake of premium-priced products
3.2.3 Effective immunotherapies
3.2.4 Label extension of current therapies into the new settings
3.2.5 Government initiatives
3.3 Market restraints
3.3.1 Lack of awareness in some developing regions
3.3.2 High cost associated with the therapy
3.3.3 Economic crisis
3.3.4 Regulatory issues
3.4 Market Opportunitites
3.5 Market Threats
4. Porters Five Force Analysis
4.1 Bargaining Power of suppliers
4.2 Bargaining power of buyers
4.3 Degree of competition
4.4 Threat of substitution
4.5 Threat of new entrants
5. Market Segmentation
5.1 By Cancer Type
5.1.1 Superficial spreading melanoma
5.1.2 Nodular melanoma
5.1.3 Lentigno maligna melanoma
5.1.4 Acral lentiginous melanoma
5.1.5 Amelanotic melanoma
5.1.6 Others
5.1.6.1 Cutaneous malignant melanoma
5.1.6.2 Melanoma of vulva
5.1.6.3 Vaginal melanoma or melanoma of black passage
5.2 By Cancer stage
5.2.1 Stage 0
5.2.1 Stage I
5.2.1 Stage II
5.2.1 Stage III
5.2.1 Stage IV
5.3 By Diagnosis
5.3.1 Dermatoscopy
5.3.2 Sentinel lymph node Biopsy
5.3.3 Blood Tests
5.3.4 X-rays
5.3.5 Ultrasound
5.3.6 CT Scan
5.4 By Treatment
5.4.1 For early melanoma
5.4.1.1 Surgery
5.4.1.1.1 Excision
5.4.1.1.2 Mohs surgery
5.4.2 For advanced melanoma
5.4.2.1 Chemotherapy
5.4.2.2 Biological therapy
5.4.2.3 Radiotherapy
5.4.2.4 Targeted therapy,
5.4.2.5 Immune therapy
5.4.2.6 Surgery
5.4.2.6.1 Lymphadenectomy
5.5 By Geography
5.5.1 Latin America
5.5.1.1 Mexico
5.5.1.2 Brazil
5.5.1.3 Argentina
6. Competitive Landscape
7. Company Profiles
7.1 Abbott Diagnostics
7.2 Agilent Technologies
7.3 Roche
7.4 GlaxoSmithKline
7.5 AstraZeneca
7.6 Bristol-Myers Squibb
7.7 Eli Lilly
7.8 Merck
7.9 Novartis
7.10 Pfizer
7.11 Sanofi
7.12 Qiagen N.V. Company
7.13 Teva Pharmaceuticals
8. Appendix
8.1 Abbrevations
8.3 Bibliography
8.4 Disclaimer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll